This is a preview of subscription content, log in via an institution to check access.
References
Lazarous DF, Shou M, Stiber JA, et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 1997 Oct; 36: 78–85
Ishibashi Y, Harada S, Takemura T, et al. The clinical effects of KCB-1 (bFGF) on skin ulcers: an open trial by 12-week application [in Japanese]. Rinsho Iyaku 1996; 12 (10): 2117–29
Ishibashi Y, Soeda S, Ohura T, et al. The clinical effects of bFGF (KCB-1) on various intractable skin ulcers: comparison of new and old bulk formulations [in Japanese]. Rinsho Iyaku 1996; 12 (9): 1835–54
Ishibashi Y, Soeda S, Ohura T, et al. The clinical effects of KCB-1 on skin ulcers: a double blind trial to investigate an optimal dose [in Japanese]. Rinsho Iyaku 1996; 12 (9): 1809–34
FIBLAST Safety Study Group. Clinical safety trial of intravenous basic fibroblast growth factor (bFGF, FIBLAST®) in acute stroke. Stroke 1998 Jan; 29: 287
Rudolphi K, Grome JJ, Gojowczyk G. Post-treatment with i.v. infusion of human recombinant bFGF reduces infarct size following permanent middle cerebral artery occlusion in rats. Cerebrovasc Dis 1996; 6 Suppl. 2: 41
Rights and permissions
About this article
Cite this article
Trafermin. Drugs R&D 1, 40–41 (1999). https://doi.org/10.2165/00126839-199901010-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901010-00016